Skip to main content
Top
Published in: Virchows Archiv 2/2003

01-08-2003 | Original Article

Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray

Authors: Jorge S. Reis-Filho, Pete T. Simpson, Albino Martins, Ana Preto, Fátima Gärtner, Fernando C. Schmitt

Published in: Virchows Archiv | Issue 2/2003

Login to get access

Abstract

p63, cytokeratin (CK) 5/6 and CK 14 have been employed in diagnostic pathology as markers of basal, squamous and myoepithelial differentiation in several types of human neoplasms; however, there is scant data on the concurrent expression of these markers in large series of human neoplasms. We analyzed the distribution of these three immunohistochemical markers in 51 normal human tissue samples, 350 carcinomas, 25 malignant melanomas (MMs), and 25 glioblastomas using three serial sections of tissue array research program (TARP)-4 multi-tumor tissue microarray. Also, we performed double immunostainings to characterize the differential distribution of p63/CK 5/6 and p63/CK 14 in normal breast, salivary gland and skin. p63, CK 5/6 and CK 14 were expressed in basal cells of the prostate and respiratory epithelia and in breast and bronchial myoepithelial cells. p63 was also expressed in cytotrophoblast cells of human placenta and in scattered cells of lymph node germinal center. CK 5/6 and CK 14 also stained the cytoplasm of basal cells of esophageal stratified squamous epithelium and transitional epithelial cells of the bladder. No mesenchymal, neural, endothelial, smooth muscle or adipose cells were stained by any of the markers. p63, CK 5/6, and CK 14 were respectively expressed in 92.6%, 75.0%, and 52.9% of the squamous cell carcinomas of the lung, 10.2%, 20.0%, and 7.4% of the ductal carcinomas of the breast, 12.9%, 34.4%, and 11.8% of the serous and 25.0%, 0%, and 0% of the endometrioid carcinomas of the ovary. Lung, prostate and colonic adenocarcinomas, as well as MMs and glioblastomas were only rarely decorated by one of the markers. Only matched samples of 16 squamous cell carcinomas and two ductal carcinomas of the breast co-expressed these three markers. In double immunostainings, p63-CK 5/6, as well as p63-CK 14 were co-expressed by basal/myoepithelial cells of the salivary glands and basal cells of the epidermis. Our results demonstrate that p63, CK 5/6 and CK 14 may be used together in immunohistochemical panels to characterize squamous differentiation in poorly differentiated carcinomas or carcinomas of unknown origin.
Literature
1.
go back to reference Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C (2001) p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25:1054–1060CrossRefPubMed Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, Doglioni C (2001) p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25:1054–1060CrossRefPubMed
2.
go back to reference Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82:737–746PubMed Bocker W, Moll R, Poremba C, Holland R, Van Diest PJ, Dervan P, Burger H, Wai D, Ina Diallo R, Brandt B, Herbst H, Schmidt A, Lerch MM, Buchwallow IB (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82:737–746PubMed
3.
go back to reference Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72–79CrossRefPubMed Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72–79CrossRefPubMed
4.
go back to reference Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943–1999PubMed Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943–1999PubMed
5.
go back to reference Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK (2002) Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 33:158–164CrossRefPubMed Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK (2002) Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 33:158–164CrossRefPubMed
6.
go back to reference Chu PG, Weiss LM (2002) Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 15:6–10PubMed Chu PG, Weiss LM (2002) Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 15:6–10PubMed
7.
go back to reference Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40:403–439CrossRefPubMed Chu PG, Weiss LM (2002) Keratin expression in human tissues and neoplasms. Histopathology 40:403–439CrossRefPubMed
8.
go back to reference Chu PG, Lyda MH, Weiss LM (2001) Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial neoplasms. Histopathology 39:9–16CrossRefPubMed Chu PG, Lyda MH, Weiss LM (2001) Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial neoplasms. Histopathology 39:9–16CrossRefPubMed
9.
go back to reference Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG (2000) Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and cd44 h in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 13:107–112PubMed Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG (2000) Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and cd44 h in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 13:107–112PubMed
10.
go back to reference De Laurenzi V, Rossi A, Terrinoni A, Barcaroli D, Levrero M, Costanzo A, Knight RA, Guerrieri P, Melino G (2000) p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun 273:342–346CrossRefPubMed De Laurenzi V, Rossi A, Terrinoni A, Barcaroli D, Levrero M, Costanzo A, Knight RA, Guerrieri P, Melino G (2000) p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochem Biophys Res Commun 273:342–346CrossRefPubMed
11.
go back to reference Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8:494–501PubMed Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8:494–501PubMed
12.
go back to reference Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD (2001) Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 32:1157–1165CrossRefPubMed Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD (2001) Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 32:1157–1165CrossRefPubMed
13.
go back to reference Heatley M, Maxwell P, Whiteside C, Toner P (1995) Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol 48:26–32PubMed Heatley M, Maxwell P, Whiteside C, Toner P (1995) Cytokeratin intermediate filament expression in benign and malignant breast disease. J Clin Pathol 48:26–32PubMed
14.
go back to reference Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 97:5462–5467CrossRefPubMed Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D (2000) AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A 97:5462–5467CrossRefPubMed
15.
go back to reference Hoos A, Cordon-Cardo C (2001) Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 81:1331–1338PubMed Hoos A, Cordon-Cardo C (2001) Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 81:1331–1338PubMed
16.
go back to reference Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C (2001) Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158:1245–1251PubMed Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C (2001) Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158:1245–1251PubMed
17.
go back to reference Jones C, Foschini MP, Chaggar R, Lu YJ, Wells D, Shipley JM, Eusebi V, Lakhani SR (2000) Comparative genomic hybridization analysis of myoepithelial carcinoma of the breast. Lab Invest 80:831–836PubMed Jones C, Foschini MP, Chaggar R, Lu YJ, Wells D, Shipley JM, Eusebi V, Lakhani SR (2000) Comparative genomic hybridization analysis of myoepithelial carcinoma of the breast. Lab Invest 80:831–836PubMed
18.
go back to reference Jones C, Nonni AV, Fulford L, Merrett S, Chaggar R, Eusebi V, Lakhani SR (2001) CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85:422–427CrossRefPubMed Jones C, Nonni AV, Fulford L, Merrett S, Chaggar R, Eusebi V, Lakhani SR (2001) CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 85:422–427CrossRefPubMed
19.
go back to reference Kaufmann O, Fietze E, Mengs J, Dietel M (2001) Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116:823–830PubMed Kaufmann O, Fietze E, Mengs J, Dietel M (2001) Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116:823–830PubMed
20.
go back to reference Lakhani SR, Ashworth A (2001) Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer 1:151–157 Lakhani SR, Ashworth A (2001) Microarray and histopathological analysis of tumours: the future and the past? Nat Rev Cancer 1:151–157
21.
go back to reference Lakhani SR, O'Hare MJ (2001) The mammary myoepithelial cell—Cinderella or ugly sister? Breast Cancer Res 3:1–4 Lakhani SR, O'Hare MJ (2001) The mammary myoepithelial cell—Cinderella or ugly sister? Breast Cancer Res 3:1–4
22.
go back to reference Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G (2000) The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113:1661–1670PubMed Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G (2000) The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 113:1661–1670PubMed
23.
go back to reference Lopes JM, Nesland JM, Reis-Filho JS, Holm R (2002) Differential Ki67 and bcl-2 immunoexpression in solid-glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin. Histopathology 40:464–471CrossRefPubMed Lopes JM, Nesland JM, Reis-Filho JS, Holm R (2002) Differential Ki67 and bcl-2 immunoexpression in solid-glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin. Histopathology 40:464–471CrossRefPubMed
24.
go back to reference Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708–713 Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398:708–713
25.
go back to reference Moch H, Kononen J, Kallioniemi OP, Sauter G (2001) Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 8:14–20 Moch H, Kononen J, Kallioniemi OP, Sauter G (2001) Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 8:14–20
26.
go back to reference Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11–24PubMed Moll R, Franke WW, Schiller DL, Geiger B, Krepler R (1982) The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31:11–24PubMed
27.
go back to reference O'Connell JT, Mutter GL, Cviko A, Nucci M, Quade BJ, Kozakewich HP, Neffen E, Sun D, Yang A, McKeon FD, Crum CP (2001) Identification of a basal/reserve cell immunophenotype in benign and neoplastic endometrium: a study with the p53 homologue p63. Gynecol Oncol 80:30–36CrossRefPubMed O'Connell JT, Mutter GL, Cviko A, Nucci M, Quade BJ, Kozakewich HP, Neffen E, Sun D, Yang A, McKeon FD, Crum CP (2001) Identification of a basal/reserve cell immunophenotype in benign and neoplastic endometrium: a study with the p53 homologue p63. Gynecol Oncol 80:30–36CrossRefPubMed
28.
go back to reference Ordóñes NG (1998) Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 22:1215–1221CrossRefPubMed Ordóñes NG (1998) Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 22:1215–1221CrossRefPubMed
29.
go back to reference Parsons JK, Gage WR, Nelson WG, De Marzo AM (2001) p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 58:619–624CrossRefPubMed Parsons JK, Gage WR, Nelson WG, De Marzo AM (2001) p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 58:619–624CrossRefPubMed
30.
go back to reference Pelosi G, Fraggetta F, Maffini F, Solli P, Cavallon A, Viale G (2001) Pulmonary epithelial-myoepithelial tumor of unproven malignant potential: report of a case and review of the literature. Mod Pathol 14:521–526PubMed Pelosi G, Fraggetta F, Maffini F, Solli P, Cavallon A, Viale G (2001) Pulmonary epithelial-myoepithelial tumor of unproven malignant potential: report of a case and review of the literature. Mod Pathol 14:521–526PubMed
31.
go back to reference Pelosi G, Pasini F, Stenholm CO, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, Pruneri G, Fraggetta F, Cavallon A, Roz E, Iannucci A, Bresaola E, Viale G (2002) p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 198:100–109 Pelosi G, Pasini F, Stenholm CO, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, Pruneri G, Fraggetta F, Cavallon A, Roz E, Iannucci A, Bresaola E, Viale G (2002) p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 198:100–109
32.
go back to reference Reis-Filho JS, Schmitt FC (2002) Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 9:280–289PubMed Reis-Filho JS, Schmitt FC (2002) Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 9:280–289PubMed
33.
go back to reference Reis Filho JS, Schmitt FC (2003) p63 expression in sarcomatoid/metaplastic carcinomas of the breast. Histopathology 42:94–95PubMed Reis Filho JS, Schmitt FC (2003) p63 expression in sarcomatoid/metaplastic carcinomas of the breast. Histopathology 42:94–95PubMed
34.
go back to reference Reis Filho JS, Albergaria A, Milanezi F, Amendoeira I, Schmitt FC (2002) Naked nuclei revisited: p63 immunoexpression. Diagn Cytopathol 27:135–138CrossRefPubMed Reis Filho JS, Albergaria A, Milanezi F, Amendoeira I, Schmitt FC (2002) Naked nuclei revisited: p63 immunoexpression. Diagn Cytopathol 27:135–138CrossRefPubMed
35.
go back to reference Reis Filho JS, Milanezi F, Albergaria A, Amendoeira I, Schmitt FC (2002) p63 staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. J Clin Pathol 55:936–939CrossRefPubMed Reis Filho JS, Milanezi F, Albergaria A, Amendoeira I, Schmitt FC (2002) p63 staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. J Clin Pathol 55:936–939CrossRefPubMed
36.
go back to reference Reis-Filho JS, Torio B, Albergaria A, Schmitt FC (2002) p63 expression in normal skin and usual skin carcinomas. J Cutan Pathol 29:517–523CrossRefPubMed Reis-Filho JS, Torio B, Albergaria A, Schmitt FC (2002) p63 expression in normal skin and usual skin carcinomas. J Cutan Pathol 29:517–523CrossRefPubMed
37.
go back to reference Reis-Filho JS, Milanezi F, Paredes J, Silva P, Pereira EM, Maeda AS, de Carvalho LV, Schmitt FC (2003) Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 11:1–8CrossRefPubMed Reis-Filho JS, Milanezi F, Paredes J, Silva P, Pereira EM, Maeda AS, de Carvalho LV, Schmitt FC (2003) Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 11:1–8CrossRefPubMed
38.
go back to reference Romano V, Bosco P, Rocchi M, Costa G, Leube RE, Franke WW, Romeo G (1988) Chromosomal assignments of human type I and type II cytokeratin genes to different chromosomes. Cytogenet Cell Genet 48:148–151PubMed Romano V, Bosco P, Rocchi M, Costa G, Leube RE, Franke WW, Romeo G (1988) Chromosomal assignments of human type I and type II cytokeratin genes to different chromosomes. Cytogenet Cell Genet 48:148–151PubMed
39.
go back to reference Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775PubMed Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775PubMed
40.
go back to reference Tot T (2002) Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 38:758–763CrossRefPubMed Tot T (2002) Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer 38:758–763CrossRefPubMed
41.
go back to reference van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991–1996PubMed van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991–1996PubMed
42.
go back to reference Vlasoff DM, Baschinsky DY, Frankel WL (2002) Cytokeratin 5/6 immunostaining in hepatobiliary and pancreatic neoplasms. Appl Immunohistochem Mol Morphol 10:147–151CrossRefPubMed Vlasoff DM, Baschinsky DY, Frankel WL (2002) Cytokeratin 5/6 immunostaining in hepatobiliary and pancreatic neoplasms. Appl Immunohistochem Mol Morphol 10:147–151CrossRefPubMed
43.
go back to reference Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, Burstein DE (2002) p63 In pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 33:921–926CrossRefPubMed Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, Burstein DE (2002) p63 In pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 33:921–926CrossRefPubMed
44.
go back to reference Wang TY, Chen BF, Yang YC, Chen H, Wang Y, Cviko A, Quade BJ, Sun D, Yang A, McKeon FD, Crum CP (2001) Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 32:479–486CrossRefPubMed Wang TY, Chen BF, Yang YC, Chen H, Wang Y, Cviko A, Quade BJ, Sun D, Yang A, McKeon FD, Crum CP (2001) Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 32:479–486CrossRefPubMed
45.
go back to reference Wang X, Mori I, Tang W, Yang Q, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kennichi K (2001) Metaplastic carcinoma of the breast: p53 analysis identified the same point mutation in the three histologic components. Mod Pathol 14:1183–1186PubMed Wang X, Mori I, Tang W, Yang Q, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kennichi K (2001) Metaplastic carcinoma of the breast: p53 analysis identified the same point mutation in the three histologic components. Mod Pathol 14:1183–1186PubMed
46.
go back to reference Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A (2002) Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer 99:22–28CrossRefPubMed Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A (2002) Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer 99:22–28CrossRefPubMed
47.
go back to reference Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714–718 Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398:714–718
48.
go back to reference Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79–85PubMed Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79–85PubMed
Metadata
Title
Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray
Authors
Jorge S. Reis-Filho
Pete T. Simpson
Albino Martins
Ana Preto
Fátima Gärtner
Fernando C. Schmitt
Publication date
01-08-2003
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 2/2003
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-003-0859-2

Other articles of this Issue 2/2003

Virchows Archiv 2/2003 Go to the issue